Abstract: Processes for preparing commercial quantities of a stable, pharmaceutically acceptable sevoflurane substantially free of impurities are claimed. In another embodiment, a process for removing reactive metal salts from the surface of metallic equipment used in the distillation of sevoflurane and rendering a non-inert metallic surface of the metallic equipment inert.

Abstract: A process for preparing a fluorinated diol compound by reacting the corresponding ketone-alcohol or aldehyde-alcohol with hydrogen over a palladium catalyst in the vapor phase.

Abstract: A process for preparing a fluorinated diol compound by reacting the corresponding ketone-alcohol or aldehyde-alcohol with hydrogen over a palladium catalyst in the vapor phase.

Abstract: An azeotrope comprising desflurane (CF3CFHOCF2H) and hydrogen fluoride (HF). The azeotrope can be prepared by fractionally distilling a crude mixture of desflurane and HF. Purer desflurane can be readily and easily separated from the azeotrope. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: Processes for preparing commercial quantities of a stable, pharmaceutically acceptable sevoflurane substantially free of impurities are claimed. In another embodiment, a process for removing reactive metal salts from the surface of metallic equipment used in the distillation of sevoflurane and rendering a non-inert metallic surface of the metallic equipment inert.

Abstract: A process for purifying crude fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether (sevoflurane). The crude sevoflurane is repeatedly washed with water under conditions and for a time sufficient to reduce the level of 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) to no more than 200 ppm or no more than 100 ppm.

Abstract: 1,1,1,3,3,3-Hexafluoroisopropanol (HFIP) substantially free of 1,1,1-trifluoroacetone (TFA) can be separated from a mixture containing both compounds by A) catalytic reduction with hydrogen followed by fractional distillation; B) cooling to a temperature at which HFIP freezes and TFA remains liquid; C) forming a high boiling complex comprising HF and TFA followed by fractional distillation; or D) producing HF-free conditions to yield a HFIP/TFA azeotrope followed by fractional distillation. It is emphasized that this abstract is provided to comply with the rules requiring an abstract, which will allow a searcher or other reader to quickly ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the claims. 37 CFR § 1.72(b).

Abstract: Processes for preparing commercial quantities of a stable, pharmaceutically acceptable sevoflurane substantially tree of impurities are claimed. In another embodiment, a process for removing reactive metal, salts from the surface of metallic equipment used in the distillation of sevoflurane and rendering a non-inert metallic surface of the metallic equipment inert.

Abstract: A process for purifying crude fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether (sevoflurane). The crude sevoflurane is repeatedly washed with water under conditions and for a time sufficient to reduce the level of 1,1,1,3,3,3-hexafluoroisopropanol (HFIP) to no more than 200 ppm or no more than 100 ppm.

Abstract: An azeotrope comprising desflurane (CF3CFHOCF2H) and hydrogen fluoride (HF). The azeotrope can be prepared by fractionally distilling a crude mixture of desflurane and HF. Purer desflurane can be readily and easily separated from the azeotrope. It is emphasized that this abstract is provided to comply with the rules requiring an abstract which will allow a searcher or other reader quickly to ascertain the subject matter of the technical disclosure. It is submitted with the understanding that it will not be used to interpret or limit the scope or meaning of the appended issued claims.

Abstract: A process for preparing isoflurane (1-chloro-2,2,2-trifluoroethyl difluoromethyl ether) by reacting PFE (2,2,2-trifluoroethyl difluoromethyl ether) with chlorine in the presence of ultraviolet light and added water, at a low temperature and/or at a high conversion.

Abstract: Fluorinated ketones, for example, 1,1,1-trifluoroacetone, can be stabilized against storage degradation by combining with a content of hexafluoroisopropanol (HFIP). Containers containing the stabilized mixture show prolonged storage times compared to containers containing the fluorinated ketones alone. The stabilized mixture can be used as a starting material for reactions requiring fluorinated ketones, for example, 1,1,1-trifluoroacetone, as a starting material.

Abstract: A process for preparing 2-difluoromethoxy-1,1,1,2-tetrafluoroethane (desflurane) comprising the following steps: (a) providing a first mixture comprising desflurane and 2,2-dichloro-1,1,1-trifluoroethane (R-123); (b) adding water to the first mixture to form a second mixture; and (c) fractionally distilling the second mixture to yield a desflurane product purer in R-123 than said the mixture. Also described is a purified desflurane product prepared by the process, and intermediate products comprising water added to a mixture of desflurane and R-123.